Abstract
TRPV1 has emerged as a promising therapeutic target for pain as well as a broad range of other conditions such as asthma or urge incontinence. The identification of resiniferatoxin as an ultrapotent ligand partially able to dissect the acute activation of TRPV1 from subsequent desensitization and the subsequent intense efforts in medicinal chemistry have revealed that TRPV1 affords a dramatic landscape of opportunities for pharmacological manipulation. While agonism and antagonism have represented the primary directions for drug development, the pharmacological complexity of TRPV1 affords additional opportunities. Partial agonism/partial antagonism, its modulation by signaling pathways, variable desensitization, and slow kinetics of action can all be exploited through drug design.
Keywords: Resiniferatoxin, capsaicin, partial agonist, partial antagonist, TRPV1, efficacy, signaling pathway, asthma or urge incontinence, activation of TRPV1, subsequent desensitization, pharmacological manipulation, agonism and antagonism, slow kinetics of action, drug design
Current Topics in Medicinal Chemistry
Title: TRPV1 Activation is Not An All-Or-None Event: TRPV1 Partial Agonism/Antagonism and Its Regulatory Modulation
Volume: 11 Issue: 17
Author(s): Peter M. Blumberg, Larry V. Pearce and Jeewoo Lee
Affiliation:
Keywords: Resiniferatoxin, capsaicin, partial agonist, partial antagonist, TRPV1, efficacy, signaling pathway, asthma or urge incontinence, activation of TRPV1, subsequent desensitization, pharmacological manipulation, agonism and antagonism, slow kinetics of action, drug design
Abstract: TRPV1 has emerged as a promising therapeutic target for pain as well as a broad range of other conditions such as asthma or urge incontinence. The identification of resiniferatoxin as an ultrapotent ligand partially able to dissect the acute activation of TRPV1 from subsequent desensitization and the subsequent intense efforts in medicinal chemistry have revealed that TRPV1 affords a dramatic landscape of opportunities for pharmacological manipulation. While agonism and antagonism have represented the primary directions for drug development, the pharmacological complexity of TRPV1 affords additional opportunities. Partial agonism/partial antagonism, its modulation by signaling pathways, variable desensitization, and slow kinetics of action can all be exploited through drug design.
Export Options
About this article
Cite this article as:
M. Blumberg Peter, V. Pearce Larry and Lee Jeewoo, TRPV1 Activation is Not An All-Or-None Event: TRPV1 Partial Agonism/Antagonism and Its Regulatory Modulation, Current Topics in Medicinal Chemistry 2011; 11 (17) . https://dx.doi.org/10.2174/156802611796904825
DOI https://dx.doi.org/10.2174/156802611796904825 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
Current Drug Targets Roles and Biomedical Applications of Haemolymph Lectin
Current Pharmaceutical Biotechnology Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Recent Advances in Ozonation of Vegetable Oils
Recent Patents on Materials Science Use of Ceramides and Related Products for Childhood-Onset Eczema
Recent Patents on Inflammation & Allergy Drug Discovery The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol
Current Vascular Pharmacology Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Obesity: Its Consequences Upon Respiratory System Function
Current Respiratory Medicine Reviews Pharmacology and Therapeutic Applications of A3 Receptor Subtype
Current Topics in Medicinal Chemistry Immediate Hypersensitivity Reactions to Penicillins and Other Betalactams
Current Pharmaceutical Design Diabetogenic Effects of Parthinium hysterophorous Induced Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued) The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Purine Derivatives as Ligands for A3 Adenosine Receptors
Current Topics in Medicinal Chemistry Review and Research on Feature Selection Methods from NMR Data in Biological Fluids. Presentation of an Original Ensemble Method Applied to Atherosclerosis Field
Current Drug Metabolism VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry The Mechanism of Adjuvanticity of Aluminium-Containing Formulas
Current Pharmaceutical Design The Targets of Curcumin
Current Drug Targets